The first domestic anti-PD-L1 monoclonal antibody was approved for listing! New hope for advanced lung cancer

On December 9, the State Drug Administration officially approved the marketing application of duvalizumab injection (chemical name: durvalumab, trade name: imfinzi, Chinese trade name: yingfeifan, commonly known as "drug I") for the treatment of stage III non-small cell lung cancer (NSCLC) patients without disease progression after synchronous radiotherapy and chemotherapy Duvalizumab is a PD-L1 monoclonal antibody developed by AstraZeneca It can block the inhibitory signal mediated by PD-1, increase the function of effector T cells, and restore the killing effect of T cells on tumor cells On December 26, 2018, the drug evaluation center (CDE) of the State Food and Drug Administration officially undertook the listing application of duvalizumab On November 24, 2019, the review status of duvalizumab in CDE was updated to "in approval" On December 9, 2019, the State Food and Drug Administration approved the listing of duvalizumab Duvalizumab is the first approved PD-L1 inhibitor in mainland China Its popularization and application in the Chinese market will continue to alleviate the long-term recurrence and survival difficulties of patients with locally advanced lung cancer, and will also make the locally advanced lung cancer more and more close to the potential clinical cure At present, duvalizumab is carrying out a number of clinical trials all over the world, among which the domestic ones, including HCC, advanced urothelial cancer, small cell lung cancer, etc., are all in phase III clinical trials It is hoped that duvalizumab can be approved for more tumor indications, further improve the accessibility of drugs, and bring new gospel to Chinese patients! Editor in chief: Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.